Skip to Content

'
Thomas J Pugh, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1840 Old Spanish Trail
Unit Number: 1150
Houston, TX 77054
Room Number: PTC 1.2032

Education & Training

Degree-Granting Education

2005 University of Colorado Health Science Center, Denver, CO, MD, Medical Doctorate
1999 University of Kansas, Lawrence, KS, BA, Bachelor of Arts, Psychology

Postgraduate Training

12/2009-1/2010 Clinical Fellowship, Prostate Brachytherapy, American Brachytherapy Society Seattle Prostate Institute, Seattle, WA
7/2009-6/2010 Chief Resident, Radiation Oncology, University of Colorado Denver, Denver, CO
6/2006-6/2009 Clinical Residency, Radiation Oncology, University of Colorado Denver, Denver, CO
6/2005-6/2006 Clinical Internship, Internal Medicine, University of Colorado Denver, Denver, CO

Board Certifications

5/2011 American Board of Radiology
10/2006 National Board of Medical Examiners

Honors and Awards

2009 Methods in Clinical Cancer Research Workshop, ASCO/AACR
2009 Prostate Brachytherapy Honorarium, American Brachytherapy Society
2009 RTOG Travel Grant Spring 2009, Radiation Therapy Oncology Group
2009 Young Oncologist Essay Award, American Radium Society
2008 Poster Recognition Award, American Society for Radiation Oncology
2001 T-32 Institutional Research Grant, National Institute of Health
1999 GTE Academic All American: Men's Basketball District 7, National Collegiate Athletic Association
1999 NCAA Post-Graduate Scholarship, National Collegiate Athletic Association
1999 Phi Beta Kappa Honor Society

Professional Memberships

American Brachytherapy Society
Member, 12/2009-present
American Society for Radiation Oncology
Member, 7/2006-present
American Society of Clinical Oncology
Member, 7/2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. e-Pub 10/15/2013. PMID: 24139077.
2. Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. e-Pub 9/17/2013. PMID: 24050892.
3. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. e-Pub 8/2013. PMID: 23939133.
4. Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer. e-Pub 6/24/2013. PMID: 23798338.
5. Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK. Multi-Field Optimization Intensity-Modulated Proton Therapy (MFO-IMPT) for Prostate Cancer: Robustness Analysis through Simulation of Rotational and Translational Alignment Errors. Med Dosim. e-Pub 6/2013. PMID: 23747223.
6. Register SP, Kudchadker RJ, Levy LB, Swanson DA, Pugh TJ, Bruno TL, Frank SJ. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy 12(3):210-6, May-Jun, 5/2013. e-Pub 3/1/2013. PMID: 23466360.
7. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy 12(3):204-9, May-Jun, 5/2013. e-Pub 6/5/2012. PMID: 22673704.
8. Takiar V, Pugh TJ, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. Brachytherapy. e-Pub 5/2013. PMID: 23669149.
9. Pugh TJ, Choi S, Nguyen QN, Gillen MT, Zhu XR, Palmer M, Lee AK. Proton Therapy for Prostate Cancer. Practical Radiation Oncology 3(2):e87-94, 4/2013. e-Pub 7/2012.
10. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation Therapy Modalities in Prostate Cancer. JNCCN 1(11(4)):414-21, 4/2013. PMID: 23584344.
11. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era? Int J Radiat Oncol Biol Phys 85(3):693-9, 3/2013. e-Pub 7/2012. PMID: 22836052.
12. Brown AP, Pugh TJ, Swanson DA, Kudchadker RJ, Bruno TL, Christensen EN, van Vulpen M, Frank SJ. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy. e-Pub 2/2013. PMID: 23380383.
13. Albert JM, Swanson DA, Pugh TJ, Zhang M, Bruno TL, Kudchadker RJ, Frank SJ. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy 12(1):30-7, 1/2013. e-Pub 6/21/2012. PMID: 22727474.
14. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-52, 9/2012. e-Pub 2/21/2012. PMID: 22357249.
15. Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: a case report and review of the literature. Head and Neck 34(7):1045-50, 7/2012. e-Pub 7/2011. PMID: 21384456.
16. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? Eur J Cancer 48(11):1664-71, 7/2012. e-Pub 2/2012. PMID: 22336663.
17. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of rectal complications following brachytherapy. Practical Radiation Oncology 2(3):e7-e13, 7/2012. e-Pub 7/2012.
18. Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, Frank SJ. Sexual Function and the use of Medical Devices or Drugs to Optimize Potency after Prostate. Int J Radiat Oncol Biol Phys 82(5):e765-71, 4/2012. e-Pub 1/2012. PMID: 22300559.
19. Kudchadker RJ, Pugh TJ, Swanson DA, Bruno TL, Bolukbasi Y, Frank SJ. Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. Medical Dosimetry 37(4):387-90, 3/2012.
20. Frank SJ, Levy LB, van Vulpen M, Crook J, Sylvester J, Grimm P, Pugh TJ, Swanson DA. Outcomes after prostate brachytherapy are even better than predicted. Cancer 118(3):839-47, 2/2012. e-Pub 7/2011. PMID: 21751187.
21. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, Jan-Feb, 1/2012. PMID: 22290249.
22. Pugh TJ, Lee AK. Role of radiation therapy for the treatment of lymph nodes in urologic malignancies. Urol Clin North Am 38(4):497-506, 11/2011. PMID: 22045180.
23. Samuelian JM, Swanson DA, Kudchadker RJ, Pugh TJ, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term Tumor Control After Brachytherapy for Cancer at the Base of the Prostate. Journal of Contemporary Brachytherapy 3(4). e-Pub 4/2011.
24. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 78(2):521-6, 10/2010. e-Pub 2/2010. PMID: 20133082.
25. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer 116(16):3843-51, 8/15/2010. PMID: 20564102.
26. Pugh TJ, Ballonoff A, Rusthoven KE, McCammon R, Kavanagh B, Newman F, Rabinovitch R. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Int J Radiat Oncol Biol Phys 76(3):845-9, 3/1/2010. e-Pub 6/8/2009. PMID: 19515509.
27. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572-8, 4/1/2009. e-Pub 3/2/2009. PMID: 19255321.
28. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579-84, 4/1/2009. e-Pub 3/2/2009. PMID: 19255320.

Invited Articles

1. Pugh TJ, Frank SJ. Quality of life issues in the radiotherapuetic management of prostate cancer. Radiation Medicine Grand Rounds 2(1), 4/2011.
2. Pugh TJ, Raben D. Management of pT3 Prostate Cancer. AUA Update Series 30(12):105-112, 2011.
3. Pugh TJ, Gaspar LE. Prophylactic cranial irradiation for patients with lung cancer. Clin Lung Cancer 8(6):365-8, 5/2007. PMID: 17562236.

Abstracts

1. S. Beddar, L. Wootton, R. Kudchadker, S. Choi, T. Pugh, A. K. Lee. Online In-Vivo Dosimetry of Rectal Dose Using Plastic Scintillation Detectors for Prostate Patients. 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference, 10/2013.
2. Mitcham T, Marques T, Chatterjee D, Krishnan S, Pugh T, Bouchard R. Transrectal photoacoustic-ultrasonic imaging enhancement through interstitial irradiation and targeted. Proceedings of the 2013 IEEE Ultrasonics Symposium, 7/2013.
3. Jeri Kim, John Francis Ward, Curtis A. Pettaway, Xuemei Wang, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Louis L. Pisters, Surena F. Matin, Jay Bakul Shah, Jose A. Karam, Brian Francis Chapin, John N. Papadopoulos, Mary F. Achim, Karen Elizabeth Hoffman, Thomas J. Pugh, Seungtaek Choi, Christopher Logothetis, Patricia Troncoso, John W. Davis. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). Journal of Clinical Oncology 31:Abstract 5069, 6/2013.
4. Mitcham T, Marques T, Chatterjee D, Krishnan S, Pugh T, Bouchard R. Transrectal photoacoustic-ultrasonic imaging for cancer diagnosis and therapy guidance in the prostate. 38th International Symposium on Ultrasonic Imaging and Tissue Characterization, 6/2013.
5. K. Ranh Voong MD, Deborah A. Kuban MD, James Kanke CMD, Lawrence B. Levy MS, Vinita Takiar MD PhD, Thomas J. Pugh MD. Higher baseline urinary symptoms are not associated with increased toxicity from moderately hypo-fractionationed external beam radiation for localized prostate cancer. Texas Radiological Society, 4/2013.
6. K. Ranh Voong, MD, Thomas J. Pugh, MD, Lawrence B. Levy,. Prostate Volume as a Predictor of Toxicity. American Radium Society Annual Meeting Proceddings, 4/2013.
7. Pugh TJ. The Role of Magnetic Resonance Imaging (MRI) in Prostate Radiation Treatment Planning: Moving Beyond Image Fusion. 37th Annual Meeting of the Gilbert H. Fletcher Society, 4/2013.
8. Rajat J. Kudchadker, Tze Yee Lim, Weiliang Du, Teresa L. Bruno, Usama Mahmood, Thomas J. Pugh, Steven J. Frank. 131Cs Stranded-Seed Nomogram for a Prospective Phase II Intermediate-Risk Low-Dose-Rate Prostate Brachytherapy Clinical Trial. Brachytherapy 12(S1):S73, 3/2013.
9. Tze Yee Lim, Steven J. Frank, Thomas J. Pugh, Teresa L. Bruno, Rajat J. Kudchadker. Comparison of Two Commercial Treatment Planning Systems Variseed and Mim for Low-Dose-Rate Prostate Brachytherapy. Brachytherapy 12(S1):S68, 3/2013.
10. Usama Mahmood, Lawrence Levy, Gary Walker, Matthew Koshy, Thomas Pugh, Steven Frank, William Graber, Karen Hoffman, Deborah Kuban, Andrew Lee. Declining Use of Brachytherapy for the Treatment of Prostate Cancer. Brachytherapy 12(S1):S32, 3/2013.
11. Thomas J. Pugh, Rajat Kudchadker, Usama Mahmood, Teresa L. Bruno, Steven J. Frank. Prostate Brachytherapy Treatment Planning Using T2-Weighted Cube 3D Magnetic Resonance Imaging without an Endorectal Coil. Brachytherapy 12(S1):S72-73, 3/2013.
12. S. Choi, W.E. Umfleet, M.B. Palmer, Q. Nguyen, S.E. McGuire, T.J. Pugh, D.A. Kuban, A.K. Lee. Comparison of Scanning Beam Proton Therapy (SBPT) to Intensity Modulated X-ray Therapy (IMRT) for Postoperative Salvage Treatment of Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics 84(3):S843-844, 11/2012.
13. U. Mahmood, M. Koshy, T. Pugh, K. Hoffman, D. Kuban, A. Lee. Decreasing Utilization of Brachytherapy for the Treatment of Prostate Cancer: A National Pattern of Care Analysis Using NCCN Risk Categorization. International Journal of Radiation Oncology*Biology*Physics, 84(3):S399, 11/2012.
14. V. Takiar, T.J. Pugh, D. Swanson, R. Kudchadker, T.L. Bruno, S. McAvoy, S.J. Frank. MRI-based Sector Analysis Enhances Prostate Pd-103 Brachytherapy Quality Assurance in a Phase II Prospective Trial of Intermediate Risk Patients. International Journal of Radiation Oncology*Biology*Physics 84(3):S380-381, 11/2012.
15. A.K. Lee, S. Choi, Q. Nguyen, T. Pugh, B. Mathai, S.J. Frank, K. Hoffman, D. Kuban, S. McGuire, M.F. Munsell. Patient Quality of Life After Proton Therapy (1.8 vs 2 Gray Equivalents) for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 84(3):S366-367, 11/2012.
16. T.J. Pugh, S. Choi, Q. Nguyen, B. De Gracia, M.F. Munsell, S.J. Frank, D.A. Kuban, K.E. Hoffman, S.E. McGuire, A.K. Lee. Prospective Quality of Life and Toxicity Between Passively Scattered and Spot-Scanning Proton Therapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 84(3):S384, 11/2012.
17. S.J. Frank, T. Pugh, M. Munsell, R. Kudchadker, T. Bruno, D. Kuban, A.K. Lee, S. Choi, S. McGuire, D.A. Swanson. Prostate Brachytherapy Long-term Outcomes, Quality of Life, and Patient-reported Satisfaction. International Journal of Radiation Oncology*Biology*Physics 84(3):S392-393, 11/2012.
18. Q. Nguyen, C. Wages, M. Palmer, S. Choi, T. Pugh, D.A. Kuban, A.K. Lee. Scanning Beam Proton Therapy Reduces Dose to Normal Tissue Compared to 3-dimensional X-rays or Passively-Scattered Proton Therapy in Patients With Stage I Seminoma. International Journal of Radiation Oncology*Biology*Physics, 84(3):S844-845, 11/2012.
19. S. Bian, D.A. Kuban, L.B. Levy, J. Oh, S. Choi, S.E. McGuire, T.J. Pugh, P.L. Nguyen, A.K. Lee, K.E. Hoffman. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 84(3):S370-371, 11/2012.
20. H.D. Skinner, K.E. Hoffman, L.B. Levy, A.K. Lee, S.J. Frank, S. Choi, S.E. McGuire, T.J. Pugh, D.A. Kuban. Toxicity and Dosimetric Parameters Related to Conventional Versus Dose-Escalated, Hypofractionated Radiation in Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 84(3):S147, 11/2012.
21. Q. Nguyen, M. Palmer, M. Amin, W.E. Umfleet, S. Choi, T.J. Pugh, A.K. Lee. Utilization of Constraints in the Optimization Algorithm With Scanning Beam Proton Therapy Decreases Dose to the Rectum for Patients With Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 84(3):S846-847, 11/2012.
22. Frank SJ, Madden T, Swanson DA, Martirosyan K, Uthamanthil R, Stafford J, Gagea M, Pugh TJ, Kudchadker R, Johansen MJ. C4 Markers for MRI-based Prostate Brachytherapy. Radiotherrapy and Oncology 103(S2):S91, 5/2012.
23. Pugh TJ, Swanson DA, Kudchadker RJ, Bruno TL, Munsell MF, Frank SJ. Prospective evaluation of pharmacologic penile rehabilitation following prostate brachytherapy. Radiotherapy and Oncology 103(S2):S91-S92, 5/2012.
24. Pugh TJ, Amos RA, Baptiste SJ, Choi S, Nguyen QN, Zhu XR, Palmer MB, Lee AK. Intensity Modulated Proton Therapy (IMPT) for Prostate Cancer: Robustness Analysis through Simulation of Rotational and Translational Alignment Errors. Oncology 26(S1):62-63, 4/2012.
25. Bian S, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Lee AK. Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer. J Clin Oncol 30(Suppl 5):Abstract 176, 2/2012.
26. Anand A, Du W, Chung H, Frank S, Pugh T, Kudchadker R. M.D. Anderson Prostate Seed Implant Dose Calculator. Medical Physics 39:3713, 2012.
27. M Yang, W Du, S Frank, T Pugh, T Bruno, R Kudchadker. Radiation Exposure Estimation for 131Cs Prostate Implant Patient Release Determination. Medical Physics 39:3763, 2012.
28. S. Choi, M. Amin, M. Palmer, X.R. Zhu, Q. Nguyen, T.J. Pugh, D.A. Kuban, A.K. Lee. Comparison of Intensity Modulated Proton Therapy (IMPT) to Passively Scattered Proton Therapy (PSPT) in the Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys 81(2):S154-S155, 10/2011.
29. K.O. Castle, K.E. Hoffman, L.B. Levy, A.K. Lee, S. Choi, Q.N. Nguyen, Frank SJ, T. Pugh, S.E. McGuire, D.A. Kuban. Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Radiat Oncol Biol Phys 81(2):S40-41, 10/2011.
30. A.P. Brown, T.J. Pugh, D.A. Swanson, R.J. Kudchadker, T.L. Bruno, E.N. Christensen, Frank SJ,. mproving Prostate Brachytherapy Quality Assurance with MRI-based Sector Analysis in a Phase II Prospective Trial. Int J Radiat Oncol Biol Phys 81(2):S209, 10/2011.
31. T.J. Pugh, S.J. Frank, M. Achim, D.A. Kuban, A.K. Lee, S. Choi, Q. Nguyen, K. Hoffman, S.E. McGuire, D.A. Swanson, J.D. Davis. Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI. Int J Radiat Oncol Biol Phys 81(2):S398, 10/2011.
32. E.N. Christensen, T.J. Pugh, M.F. Munsell, D.A. Swanson, R.J. Kudchadker, T.L. Bruno, A.P. Brown, Frank SJ. Sector Analysis of Prostate Brachytherapy Shows That Low Doses can Achieve an Undetectable PSA. Int J Radiat Oncol Biol Phys 81(2):S422, 10/2011.
33. Q. Nguyen, C. Crawford, M. Palmer, R. Zhu, S. Choi, T. Pugh, S.J. Frank, K. Hoffman, D.A. Kuban, A.K. Lee. Utilizing A Multifield Optimization Intensity Modulated Proton Technique (MFO-IMPT) To Deliver A Simultaneous Integrated Boost (SIB) To The Dominant Intraprostatic Lesion For Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 81(2):S876-S877, 10/2011.
34. Kudchadker RJ, Pugh TJ, Bruno TL, Du W, Swanson DA, Frank SJ. Optimizing quality assurance in a prospective phase II clinical trial for intermediate risk prostate cancer with brachytherapy as monotherapy using a Palladium-103 stranded seed nomogram. Med Phys 38(6):3625, 7/2011.
35. Kudchadker RJ, Du W, Bruno TL, Pugh TJ, Frank SJ. Treatment planning dosimetry comparison between model 9011 I-125 thinseed and Model 6711 I-125 seeds for prostate brachytherapy. Med Phys 38(6):3625, 7/2011.
36. Frank SJ, Munsell MF, Pugh TJ, Kudchadker RJ, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Swanson DA. Long-Term Outcomes, Quality of Life, and Patient-Reported Satisfaction Following Prostate Brachytherapy: The M.D. Anderson Cancer Center Experience. Brachytherapy 10(Supplement 1):S16-17, 5/2011.
37. Pugh TJ, Frank SJ, Kudchadker R, Swanson DA, Davis JW. Prostate MRI in Men With Intermediate-Risk Prostate Cancer: Implications for Prostate Brachytherapy Monotherapy. Brachytherapy 10(Supplement 1):S30, 5/2011.
38. M. M. Kim, K. E. Hoffman, L. B. Levy, S. J. Frank, S. Choi, Q. N. Nguyen, T. Pugh, S. E. McGuire, A. Lee, D. A. Kuban. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. J Clin Oncol 29(Suppl 7):Abstract 181, 2/2011.
39. Zhu XR, Grosshans D, Lee A, Choi S, Mahajan A, Chang E, Pugh T, Wu R, AMIN M, Palmer M, Taylor M, Gillin M, and Sahoo N. Spot Scanning Proton Therapy: Single Field Simultaneous Integrated Boost. Med Phys 38:3602, 2011.
40. Pugh TJ, Schefter TE, Kane M, Eckhardt SG, McCarter M, Chen YK, Swing R, Draheim L, Raben D. Phase I Trial of Concurrent Bortezomib, Paclitaxel, and External Beam Radiation in Patients with Unresectable Pancreatic or Billiary Cancer. Poster Viewing for 52nd Annual ASTRO Meeting, 10/2010.
41. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven K, Swing R, Raben D,. Phase I Study of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Oral presentation 91st Annual Meeting of the American Radium Society, 4/2009.
42. Rusthoven KE, Kavanagh B, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gasper LE, Schefter TE. Mature Results of a Multi-Institutional Phase I/II of Stereotactic Body Radiation Therapy for Liver Metastases. Poster Discussion ASCO Gastrointestinal Cancers Symposium. 1/2009.
43. Pugh TJ, McCrann K, Kane M, Pervez H, Schefter TE. Combined Modality Treatment for Unresectable Cholangiocarcinoma: A Retrospective Single Institution Experience. International Journal of Radiation Oncology, Biology, and Physics, 9/2008.
44. Pugh TJ, Ballonoff A, Newman F, Rabinovicth R. Improved Disease Specific and Overall Survival in Patients with Early Stage Low Grade Follicular Lymphoma Treated with External Beam Radiation: A Surveillance, Epidemiology, and End Results Analysis. International Journal of Radiation Oncology, Biology, and Physics, 9/2008.
45. Pugh TJ, Ballonoff A, McCammon R, Rusthoven K, Kavanagh B, Rabinovitch R. Decreased Incidence of Cardiac Mortality in Patients with Stages I and II Diffuse Large B-Cell Lymphoma Treated with Radiation: A Surveillance, Epidemiology, and End-Results (SEER) Analysis. International Journal of Radiation Oncology, Biology, and Physics, 11/2007.
46. Pugh TJ, Singh M, Rabinovitch R. First reported case of radiation induced angiosarcoma associated with BRCA2 Mutation following breast conserving therapy. ASCO Breast Cancer Symposium, 9/2007.

Book Chapters

1. Thomas J. Pugh, Carolyn I. Sartor, Bert O'Neil, David Raben. Gunderson and Tepper Clinical Radiation Oncology 3rd Edition; Chapter 5:. In: Biologics and their interaction with radiation, Third. Ed(s) LL Gunderson, JE Tepper. Elsevier, 83-94, 2011. ISBN: 978-1-4377-1637-5.
2. Paul Bunn, York Miller, Nir Peled, Ali Musani, Kavita Garg, Wilbur Franklin, Fred Hirsch, John Mitchell, Michael Weyant, Ross Camidge, Robert Doeble, Laurie Gaspar,Brian Kavanagh, TJ Pugh, Jessica Flagiello. Future Directions in the Multidisciplinary Management of Lung Cancer. In: A Multidisciplinary Approach to Diagnosis and Management. Ed(s) Kemp Kernstine, Karen Reckamp, Charles Thomas. Demos Medical Publishing, 2010. ISBN: 1936287064.

Letters to the Editor

1. Rusthoven KE, Pugh TJ. Stereotactic body radiation therapy for inoperable lung cancer. JAMA 303(23):2354-5; author reply 2355, 6/16/2010. PMID: 20551403.

Grant & Contract Support

Title: Development and Optimization of a Photoacoustic-Ultrasonic Transrectal Imaging System for the Improved Visualization of Prostate Brachytherapy Seeds
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Richard Brouchard

Last updated: 10/21/2013